RankingsPricing
  1. US-listed companies
  2. CRISPR Therapeutics AG
  3. Financials
  4. Property, plant and equipment, net

CRISPR Therapeutics AGCRSP

Market cap
$4.7B
P/E ratio
SummaryFinancials
Period EndProperty, plant and equipment, net (Million USD)YoY (%)
Dec 31, 2024134-11.75%
Dec 31, 2023152-7.14%
Dec 31, 2022164+18.94%
Dec 31, 2021138+226.32%
Dec 31, 202042+34.57%
Dec 31, 201931+69.35%
Dec 31, 201819-1.89%
Dec 31, 201719-10.32%
Dec 31, 201621

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)